ERBB2 and small cell lung carcinoma: Together, these data demonstrate that ERBB2 blockade increases MHC-I expression on SCLC cells in vivo and thereby prevents SCLC immune evasion and overcomes resistance against anti-PD-1 therapy in autochthonous Rb1/Trp53-deleted SCLC mice.